Cellnovo Group

Cellnovo is an innovative medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. Compact, intuitive and entirely connected, Cellnovo’s micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to respond to a high level of demand. For more information, visit www.cellnovo.com.